ANA as a screening test is problematic given this low specificity. Leads to so much anxiety #ACR17 @RheumNow pic.twitter.com/EtXqVtfv4O
— Dr Irwin Lim (@_connectedcare) November 7, 2017
Opening statements to consider prior to applying new SLE criteria #ACR17 @RheumNow pic.twitter.com/XF2JCj4Fo9
— Dr Irwin Lim (@_connectedcare) November 7, 2017
Blunted coronary flow reserve in # Lupus & RA #ACR17 @RheumNow pic.twitter.com/dF3W8N3sYx
— Dr. shashank akerkar (@doctorakerkar) November 7, 2017
Lupus 'Heart of the matter': Take home clinical pearls #ACR17 @RheumNow pic.twitter.com/cjzna6CjOD
— Dr. shashank akerkar (@doctorakerkar) November 7, 2017
New ACR/EULAR SLE class. criteria better sensitivity and specificity than SLICC criteria; need > 10 pts of unique domains #ACR17 @rheumnow pic.twitter.com/2KalyBB8N2
— k dao (@KDAO2011) November 7, 2017
Higher risk of heart failure in #Lupus; especially with nephritis #ACR17 @RheumNow pic.twitter.com/oZBdZAWiJ9
— Dr. shashank akerkar (@doctorakerkar) November 7, 2017
Anti Ro, anti RNP common in lupus myocarditis; MRI useful to diagnose; fair prognosis #ACR17 @RheumNow pic.twitter.com/ndXCdHCCGr
— Dr. shashank akerkar (@doctorakerkar) November 7, 2017
New draft SLE criteria #ACR17 @RheumNow pic.twitter.com/ipXQnTrp0d
— Philip Robinson (@philipcrobinson) November 7, 2017
Headaches, class VI nephritis, Ro/La, Raynaud’s NOT part of new ACR/EULAR classification criteria #ACR17 @rheumnow
— k dao (@KDAO2011) November 7, 2017
#Lupus– an independent risk factor for heart failure #ACR17 @RheumNow pic.twitter.com/vlHQ4MKSun
— Dr. shashank akerkar (@doctorakerkar) November 7, 2017
Angiogenesis, # of VEGF-exp cells, + TVIS higher in early-phase DM vs PM fascia (not muscle) #ACR17 @RheumNow #2132 https://t.co/cLaMXLt96U
— Dr. Rachel Tate (@uptoTate) November 7, 2017
ADAM-17 in inflammatory myopathies, ILD, + human lung fibroblasts. Possible tx target? #ACR17 @RheumNow #2135 https://t.co/MUP2ZrZm5e
— Dr. Rachel Tate (@uptoTate) November 7, 2017
High ANA sensitivity, low specificity in classification of SLE #ACR17 @RheumNow pic.twitter.com/9QxfJC9LrP
— Philip Robinson (@philipcrobinson) November 7, 2017
RheumNow Roundtable
Dr. Olga Petryna: Hypertension Screening in Scleroderma
Dr. Philip Robinson: Fatigue and Activity
Dr. Kathryn Dao: FDA Warnings and Precision Medicine
Dr. Ian Bruce: Lupus and Vasculitis
Dr. Olga Petryna: Cardiovascular Comorbidities
Shock-wave therapy improves finger #ulcers in patients with #scleroderma https://t.co/pLO6duEPHY #ACR17 pic.twitter.com/YWyLhDtn0X
— Healio Rheumatology (@HealioRheum) November 7, 2017
Lupus patients have an increased risk of clinically significant sleep disturbances. acr2017 @rheumnow#1649 pic.twitter.com/BAErsHkAVG
— William Shergy (@WShergy) November 7, 2017
Nice review of Castleman’s Disease vs IgG4 related disease. #thievesmarket #ACR17 @RheumNow pic.twitter.com/IiqC88hOQn
— Dr. Rachel Tate (@uptoTate) November 7, 2017
Be alert for vascular disease in your lupus patients with or without risk factors or degree of lupus activity. pic.twitter.com/S30bB2TIGk
— William Shergy (@WShergy) November 7, 2017
Summary of GCA therapy session and a few pearls. acr2017 @rheumnow pic.twitter.com/0Wglvf0OBF
— William Shergy (@WShergy) November 7, 2017
Great work! Shrinking lung syndrome in lupus is condition we should all be aware of to have on our differential. #ACR17 @rheumnow https://t.co/NeKHXmVHTl
— Dr. Paul Sufka (@psufka) November 6, 2017
Japanese study describes top infections in GPA: bacterial PNA, CMV, HZ #1778 #ACR17 @RheumNow @HealioRheum pic.twitter.com/R31p0einP0
— Cassandra Calabrese (@CCalabreseDO) November 6, 2017
Pregnancy outcomes in SLE patients, their sisters and unrelated controls #ACR17 @RheumNow pic.twitter.com/Lag60NKvmH
— Philip Robinson (@philipcrobinson) November 6, 2017
Dr Virginia Pascual:Precision Medicine: 7 types of SLE, 3 signatures (IFN,plasmablast, neutrophil), 1 amazing lady. #ACR17 @rheumnow pic.twitter.com/z6RVguypE7
— k dao (@KDAO2011) November 6, 2017
Extracorporeal Shock Wave Therapy appears helpful for digital ulcers in systemic sclerosis #ACR17 @RheumNow #1704 pic.twitter.com/A93GZLRocg
— Dr. Paul Sufka (@psufka) November 6, 2017
Dr D Solomon #ACR17 YR in Review: anifrolumab uses IFN gene signature for proof in concept in SLE @rheumnow pic.twitter.com/nSJxreXEWj
— k dao (@KDAO2011) November 5, 2017
“Microbiome communities are linked to severity of SLE activity.” G. Silverman, MD #plenarysession #ACR17 @RheumNow
— Dr. Rachel Tate (@DrRachelTate) November 6, 2017
Changes in gut microbiome linked to active SLE nephritis @RheumNow #ACR17 #1786 pic.twitter.com/aWlsbEfNOe
— Ian N Bruce (@Lupusdoc) November 6, 2017
HCQ in pregnancy with lupus nephritis decreases fetal loss and improves dz activity #ACR17 @rheumnow #1297 pic.twitter.com/8p3FNr8mVx
— Dr. Paul Sufka (@psufka) November 6, 2017
Bingham: “birth & genesis of a completely new disease” – checkpoint inhibitor-induced rheumatic disease #ACR17 @rheumnow
— Dr Irwin Lim (@_connectedcare) November 5, 2017
Treatment of IRAEs has really been steroids & a few other Dmards #ACR17 @rheumnow pic.twitter.com/mzHoYHAPRt
— Dr Irwin Lim (@_connectedcare) November 5, 2017
Novel anti-CD40 CFZ533 improves ESSDAI and PG scores (ΔESSDAI=5.64)in phase 2a sjogren’s trial #ACR17 #1784 @RheumNow pic.twitter.com/vxx5rIvb4K
— Olga Petryna (@DrPetryna) November 6, 2017
Novel Anti-CD40 monoclonal ab CFZ533 potential benefit in Sjogren's Syndrome. #ACR17 @RheumNow #1784 https://t.co/sehIStKFM1
— Dr. Rachel Tate (@DrRachelTate) November 6, 2017
21% of SLE pts are readmitted <30 days. Take care in post dischage period @RheumNow #ACR17 #1631 pic.twitter.com/KxZXOH9tDS
— Ian N Bruce (@Lupusdoc) November 6, 2017
Top three PRO in lupus: joint pain, fatigue, swelling. Quantitative validation to follow . #ACR17 #1238 @RheumNow pic.twitter.com/7c6arhmsdL
— Olga Petryna (@DrPetryna) November 6, 2017
Fatigue in SLE strongly tracks with stress, pain, depression #ACR17 @RheumNow #1602 pic.twitter.com/NwJ3JwNkJ1
— Ian N Bruce (@Lupusdoc) November 6, 2017
iChip technology may help distinguish autoimmune conditions @RheumNow #ACR17 #1023 pic.twitter.com/mrR4s44VKL
— Ian N Bruce (@Lupusdoc) November 6, 2017
Think of antimalarials in SLE patients with late CV outcomes @RheumNow #ACR17 #1592 and #1590 pic.twitter.com/vil89oy4az
— Ian N Bruce (@Lupusdoc) November 6, 2017
Fetal distress, preeclampsia, +/- maternal dz – indications for C-section in SLE patients. #ACR17 @RheumNow #1293 https://t.co/CP5Y6Gxa8z
— Dr. Rachel Tate (@DrRachelTate) November 6, 2017
Italian multi-center long-term f/u data on 320 kids born to mom's with rheumatic diseases. #ACR17 @RheumNow #1292 https://t.co/529IyxCJe7 pic.twitter.com/AlfNcUKWiN
— Dr. Rachel Tate (@DrRachelTate) November 6, 2017
#1173 rheumatic irAEs more common w/combo anti-PD-1/CTLA-4 and assoc w/response to cancer Tx @RheumNow @HealioRheum #ACR17 pic.twitter.com/0TkDoqsV1W
— Cassandra Calabrese (@CCalabreseDO) November 6, 2017
HCQ levels drop in pregnancy – optimizing dosing for improved maternal/fetal outcomes. #ACR17 @RheumNow #1296 https://t.co/jMOW9XmBKB pic.twitter.com/YqnPjzKShP
— Dr. Rachel Tate (@DrRachelTate) November 6, 2017
Dr. Gregg Silverman: The Microbiome and SLE
